Eton Q3 2024 Earnings Report
Key Takeaways
Eton Pharmaceuticals reported a strong third quarter with product sales reaching $9.8 million, a 40% increase year-over-year. The company achieved positive GAAP net income from product revenue for the first time. They also entered an agreement to acquire Increlex and had their NDA for ET-400 accepted by the FDA.
Delivered 15th straight quarter of sequential growth in product sales and reported positive GAAP net income.
Eton reported third quarter 2024 product sales of $9.8 million, representing 40% growth over the prior year period.
Entered into an asset purchase agreement to acquire IncrelexĀ® from Ipsen S.A.
New Drug Application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA).
Eton
Eton
Eton Revenue by Segment
Forward Guidance
2025 is shaping up to be a transformational year for Eton Pharmaceuticals with the upcoming closing of the Increlex acquisition and ET-400 PDUFA date approaching.